Farewell to Chris Richardson

Chris Richardson joined the lab as a Postdoctoral Fellow in July 2014 and made huge advances in human gene editing. He developed new ways to improve NHEJ and HDR, plus discovered out that genome editing in human cells works via the Fanconi Anemia Pathway. Three major first author papers in three years – not bad! Chris will be joining Spotlight Therapeutics as a Group Leader, and may have some additional career news to share soon. We wish you success in all your future endeavors!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

June 30, 2020

Pushing Cas9 off the genome, published in Molecular Cell

Cas9 is a great DNA cutting enzyme, but it’s also a little weird. Unlike other nucleases (such as restriction enzymes), S, pyogenes Cas9 sticks on ...

May 7, 2020

Increasing HDR by timed inhibition of CDC7, published in Nature Communications

When doing genome editing, fixing sequences by HDR is better than breaking them by making indels. If you really want to break something, you could even use HDR...

March 12, 2020

Welcome to Lena

Welcome to Lena Kobel, who joins the lab as a Cell Line Engineer. Lena has a long history in genome engineering, with previous experience in Martin Jinek’s lab...

News Archive

Tweets